Evommune price target cut to $22 from $28
Leerink Partners cut its Evommune price target to $22.00 a share from $28.00, while maintaining an Outperform rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.